| Name | Lifastuzumab |
|---|
| Description | Lifastuzumab is a humanized anti-NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity[1]. |
|---|---|
| Related Catalog | |
| References |
| No Any Chemical & Physical Properties |